Fulcrum Therapeutics (FULC) Total Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Liabilities data on file, last reported at $13.5 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $13.5 million, down 4.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.5 million (down 4.91% YoY), and the FY2025 annual result was $17.3 million, down 2.26% from the prior year.
• Total Liabilities fell to $13.5 million in Q1 2026 per FULC's latest filing, from $17.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $34.5 million in Q2 2022 and troughed at $13.5 million in Q1 2026.
• A 5-year average of $21.8 million and a median of $21.7 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities grew 27.75% in 2022, then declined 29.35% in 2025.
• A 5-year view of Total Liabilities shows it stood at $27.7 million in 2022, then fell by 18.89% to $22.5 million in 2023, then fell by 21.41% to $17.7 million in 2024, then dropped by 2.26% to $17.3 million in 2025, then slipped by 22.08% to $13.5 million in 2026.
• Business Quant data shows FULC's Total Liabilities at $13.5 million in Q1 2026, $17.3 million in Q4 2025, and $16.5 million in Q3 2025.